Literature DB >> 21459258

Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary).

Lawrence A Leiter, David H Fitchett, Richard E Gilbert, Milan Gupta, G B John Mancini, Philip A McFarlane, Robert Ross, Hwee Teoh, Subodh Verma, Sonia Anand, Kathryn Camelon, Chi-Ming Chow, Jafna L Cox, Jean-Pierre Després, Jacques Genest, Stewart B Harris, David C W Lau, Richard Lewanczuk, Peter P Liu, Eva M Lonn, Ruth McPherson, Paul Poirier, Shafiq Qaadri, Rémi Rabasa-Lhoret, Simon W Rabkin, Arya M Sharma, Andrew W Steele, James A Stone, Jean-Claude Tardif, Sheldon Tobe, Ehud Ur.   

Abstract

With the objectives of clarifying the concepts related to "cardiometabolic risk," "metabolic syndrome" and "risk stratification" and presenting practical strategies to identify and reduce cardiovascular risk in multiethnic patient populations, the Cardiometabolic Working Group presents an executive summary of a detailed analysis and position paper that offers a comprehensive and consolidated approach to the identification and management of cardiometabolic risk. The above concepts overlap and relate to the atherogenic process and development of type 2 diabetes. However, there is confusion about what these terms mean and how they can best be used to improve our understanding of cardiovascular disease treatment and prevention. The concepts related to cardiometabolic risk, pathophysiology, and strategies for identification and management (including health behaviours, pharmacotherapy, and surgery) in the multiethnic Canadian population are presented. "Global cardiometabolic risk" is proposed as an umbrella term for a comprehensive list of existing and emerging factors that predict cardiovascular disease and/or type 2 diabetes. Health behaviour interventions (weight loss, physical activity, diet, smoking cessation) in people identified at high cardiometabolic risk are of critical importance given the emerging crisis of obesity and the consequent epidemic of type 2 diabetes. Vascular protective measures (health behaviours for all patients and pharmacotherapy in appropriate patients) are essential to reduce cardiometabolic risk, and there is growing consensus that a multidisciplinary approach is needed to adequately address cardiometabolic risk factors. Health care professionals must also consider ethnicity-related risk factors in order to appropriately evaluate all individuals in their diverse patient populations.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21459258     DOI: 10.1016/j.cjca.2011.01.016

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  20 in total

Review 1.  Managing cardiometabolic risk in primary care: summary of the 2011 consensus statement.

Authors:  Ananda Chatterjee; Stewart B Harris; Lawrence A Leiter; David H Fitchett; Hwee Teoh; Onil K Bhattacharyya
Journal:  Can Fam Physician       Date:  2012-04       Impact factor: 3.275

2.  Waist circumference is the best index for obesity-related cardiovascular disease risk in individuals with spinal cord injury.

Authors:  Henrike Rianne Joanna Cornelie Ravensbergen; Scott Alexander Lear; Victoria Elizabeth Claydon
Journal:  J Neurotrauma       Date:  2013-12-11       Impact factor: 5.269

3.  Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update.

Authors:  Sheldon W Tobe; James A Stone; Todd Anderson; Simon Bacon; Alice Y Y Cheng; Stella S Daskalopoulou; Justin A Ezekowitz; Jean C Gregoire; Gord Gubitz; Rahul Jain; Karim Keshavjee; Patty Lindsay; Mary L'Abbe; David C W Lau; Lawrence A Leiter; Eileen O'Meara; Glen J Pearson; Doreen M Rabi; Diana Sherifali; Peter Selby; Jack V Tu; Sean Wharton; Kimberly M Walker; Diane Hua-Stewart; Peter P Liu
Journal:  CMAJ       Date:  2018-10-09       Impact factor: 8.262

4.  Endothelial progenitor cell function inversely correlates with long-term glucose control in diabetic patients: association with the attenuation of the heme oxygenase-adiponectin axis.

Authors:  Yossi Issan; Edith Hochhauser; Ran Kornowski; Dorit Leshem-Lev; Eli Lev; Ram Sharoni; Luca Vanella; Nitin Puri; Michal Laniado-Schwartzman; Nader G Abraham; Eyal Porat
Journal:  Can J Cardiol       Date:  2012-03-23       Impact factor: 5.223

Review 5.  Minireview: Challenges and opportunities in development of PPAR agonists.

Authors:  Matthew B Wright; Michele Bortolini; Moh Tadayyon; Martin Bopst
Journal:  Mol Endocrinol       Date:  2014-08-22

6.  Comparison of anthropometric measurements in children to predict metabolic syndrome in adolescence: analysis of prospective cohort data.

Authors:  B A Wicklow; A Becker; D Chateau; K Palmer; A Kozyrskij; E A C Sellers
Journal:  Int J Obes (Lond)       Date:  2015-04-14       Impact factor: 5.095

7.  Cross-sectional association between sugar-sweetened beverage intake and cardiometabolic biomarkers in US women.

Authors:  Zhi Yu; Sylvia H Ley; Qi Sun; Frank B Hu; Vasanti S Malik
Journal:  Br J Nutr       Date:  2018-03       Impact factor: 3.718

8.  Intrinsic disorder in biomarkers of insulin resistance, hypoadiponectinemia, and endothelial dysfunction among the type 2 diabetic patients.

Authors:  Osama H Al-Jiffri; Fadwa M Al-Sharif; Essam H Al-Jiffri; Vladimir N Uversky
Journal:  Intrinsically Disord Proteins       Date:  2016-05-11

9.  Exercise-induced bronchospasm: a case study in a nonasthmatic patient.

Authors:  Mary Lou Hayden; Stuart W Stoloff; Gene L Colice; Nancy K Ostrom; Nemr S Eid; Jonathan P Parsons
Journal:  J Am Acad Nurse Pract       Date:  2012-01

10.  Prevalence of 10-year risk of cardiovascular diseases and associated risks in canadian adults: the contribution of cardiometabolic risk assessment introduction.

Authors:  Solmaz Setayeshgar; Susan J Whiting; Hassanali Vatanparast
Journal:  Int J Hypertens       Date:  2013-04-30       Impact factor: 2.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.